This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Sign In
Don’t have an account?
  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Bayer cross
BAYER FOR PROFESSIONALSYour Resource Portal
  • Ophthalmology
  • EYLEA® (aflibercept) 8 mg
  • EYLEA® (aflibercept) 2 mg
  • Oncology
  • Nubeqa® (darolutamide)
  • Xofigo®▼ (radium-223 dichloride)
  • Cardiology
  • Beyonttra®▼ (acoramidis)
  • Kerendia®▼ (finerenone)
  • Xarelto® (rivaroxaban)
  • Women's Health
  • Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
  • Jaydess®▼ (13.5mg levonorgestrel)
  • Kyleena® (19.5mg levonorgestrel)
  • Mirena® (52mg levonorgestrel)
  • Qlaira® (estradiol valerate/dienogest)
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
  • Ophthalmology
  • Oncology
  • Cardiology
  • Women's Health
  • Ophthalmology Resources
  • Oncology Resources
  • Cardiology Resources
  • Women's Health Resources
  • Ophthalmology Events & On Demand Webinars
  • Oncology Events & On Demand Webinars
  • Cardiology Events & On Demand Webinars
  • Women's Health Events & On Demand Webinars
  • Ophthalmology Learning Zone
  • Oncology Learning Zone
  • Cardiology Learning Zone
  • Women's Health Learning Zone
  • Ophthalmology Podcasts
  • Oncology Podcasts
  • Cardiology Podcasts
  • Women's Health Podcasts
closesearch
Recent Searches
    Homepage Banner

    Latest resources

    View more
    Real World Experience
    Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3169, June 2026
    NUBEQA® (darolutamide) Resources
    NUBEQA Prescribing Information
    PP-NUB-GB-2863, February 2026
    EYLEA® (aflibercept) Risk Minimisation Materials
    Visit to access Risk Minimisation Materials for EYLEA® (aflibercept)
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3151, May 2026
    Ophthalmology Patient Support Materials
    Access our range of downloadable patient support booklets and other resources
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3152, May 2026

    Events & webinars

    View more
    P3 Prostate Cancer Forum 2026: On-Demand Education
    Perspectives, Possibilities, Progress NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-3064, June 2026
    Podcast - Holistic management and the patient voice
    P3 Prostate Cancer Forum 2026 NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-3079, June 2026
    Session Recording - Personalising treatment in mHSPC
    P3 Prostate Cancer Forum 2026 NUBEQA® (darolutamide) Xofigo®▼ (radium223 dichloride)
    NUBEQA Prescribing Information
    Xofigo Prescribing Information
    PP-NUB-GB-3080, June 2026
    Cardiovascular Summit 2025 - HF Highlights
    Explore the Key Highlights on Heart Failure | Beyonttra®▼ (acoramidis)
    Beyonttra Prescribing Information
    Kerendia Prescribing Information
    PP-BEY-GB-0102, May 2026

    Learning Zone

    View more
    Request An Interactive Pharmacist’s Guide
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2388, May 2025
    NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
    NUBEQA Prescribing Information
    PP-NUB-GB-2129, March 2025
    Urogenital Symptoms and Sexual Difficulties
    (5 mins) Often underreported and undertreated symptoms that significantly affect a woman's relationships.
    Mirena® Prescribing Information
    PP-PF-WHC-IUS-GB-0085 October 2024
    Musculoskeletal Symptoms, Anxiety, Low Mood and Brain Fog
    (4 mins) Causes for musculoskeletal (MSK) symptoms, how menopause can worsen existing anxiety and depression.
    Mirena® Prescribing Information
    PP-PF-WHC-IUS-GB-0084 October 2024

    Podcasts

    View more
    Conversations at ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2752, March 2026
    Conversations at ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2751, March 2026
    ESMO 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2700, October 2025
    The Macular Minute: Podcast Series
    Your source for quick expert insights in medical retina
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-3090, March 2026

    Products

    View more
    Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
    Introduction to Angeliq
    Angeliq Prescribing Information
    PP-ANG-GB-0012, March 2026
    NUBEQA® (darolutamide)
    About NUBEQA
    NUBEQA Prescribing Information
    PP-NUB-GB-2950, May 2026
    Beyonttra®▼ (acoramidis) - Overview
    About Beyonttra
    Beyonttra (acoramidis) Prescribing Information
    PP-BEY-GB-0213, March 2026
    EYLEA® (aflibercept) 2 mg
    Discover data and resources about EYLEA 2 mg
    EYLEA® (aflibercept) Prescribing Information
    PP-EYL-GB-2793, March 2025

    Register with BayerPRO

    To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

     

    Don’t have an account?